<DOC>
	<DOCNO>NCT02455141</DOCNO>
	<brief_summary>To compare disease-free survival ( DFS ) rate adjuvant chemotherapy epirubicin-cyclophosphamide follow weekly paclitaxel ( EC-wP ) , weekly paclitaxel-carboplatin ( EC-wPCb ) triple-negative breast cancer .</brief_summary>
	<brief_title>Adjuvant Treatment EC Followed wP wPCb Triple-Negative Breast Cancer</brief_title>
	<detailed_description>This study plan enroll triple-negative breast cancer patient complete tumor removal . Patients randomize receive either EC-wP EC-wPCb adjuvant chemotherapy . For triple-negative breast cancer , subgroup triple-negative breast cancer DNA repairement deficiency add carboplatin paclitaxel may improve DFS basis weekly paclitaxel adjuvant chemotherapy .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>Inclusion Criteria Histologically confirm adenocarcinoma breast , completely tumor removal either modified radical mastectomy local excision plus axillary lymph node dissection ( i.e. , breast conservation therapy ) sentinel node biopsy . ( Tumorfree margin least 1 mm invasive noninvasive carcinoma except lobular carcinoma situ ( le 1 mm allow ) ; Tumor specimens available estrogen receptor ( ER ) , progesterone receptor ( PgR ) Her2 ( human epidermalgrowthfactor receptor 2 ) detection , patient triple negative breast cancer . Triplenegative disease define ER &lt; 1 % positivity , PgR &lt; 1 % positivity , negativity Her2 ( IHC ( immunohistochemistry ) 01+ FISH ( fluorescence situ hybridization ) negative ) ; Adequate bone marrow function Adequate liver renal function Eastern Cooperative Oncology Group ( ECOG ) Performance Score 01 ; Women potential childbearing must negative pregnancy test ( urine serum ) within 7 day drug administration agree use acceptable method birth control avoid pregnancy duration study ; Written inform consent accord local ethic committee requirement . Prior systemic breast cancer , include chemotherapy ; Metastatic breast cancer ; With history malignant tumor except uterine cervix cancer situ skin basal cell carcinoma ; Patients medical condition indicate intolerant adjuvant therapy relate treatment , include uncontrolled pulmonary disease , diabetes mellitus , severe infection , active peptic ulcer , coagulation disorder , connective tissue disease myelosuppressive disease ; Has active hepatitis B hepatitis C abnormal liver function test ( LFTs ) know HIV positive ; Contraindication use dexamethasone ; History congestive heart failure , uncontrolled symptomatic angina pectoris , arrhythmia myocardial infarction ; poorly control hypertension ( systolic BP &gt; 180 mmHg diastolic BP &gt; 100 mmHg ) ; Has peripheral neuropathy less grade 1 ; Patient pregnant breast feeding ; Patients psychiatric disorder disease lead incompliance therapy ; Known severe hypersensitivity drug study ; Treatment investigational drug within 30 day begin study treatment .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>chemptherapy</keyword>
	<keyword>triple negative</keyword>
	<keyword>paclitaxel</keyword>
	<keyword>carboplatin</keyword>
</DOC>